Global Health Limited

GLH.ASX

Health Care

Providing healthcare software and services for hospitals, clinicians and consumers.

Market Data

Price

$0.061

-0.0%
Market Cap

$3.6M

P/E Ratio

-100000.0x

EPS

$-0.014

Div. Yield

0.00%

52-Week Change

-0.3%

Latest Earnings

GLH December 2025 Half Year Results Summary

25 February 2026

Revenue
$3.59
-1.0% YoY

Global Health Limited reported a challenging H1 FY26 with total customer revenue declining 1% to $3.6M, though Monthly Recurring Revenue (MRR) grew 2.3% to $3.3M, now comprising 92% of customer revenue. EBITDA loss improved 18% year-on-year to -$395K as R&D expenses fell 21%, and operating cash outflows were dramatically reduced 80% to just $98K. The company expects to complete its SaaS platform transition by December 2026 and forecasts additional ARR of $400K from new partnerships and product launches. Key points: Monthly Recurring Revenue increased 2.3% to $3.3M, now representing 92% of customer revenue vs 89% previously; Operating cash outflows dramatically reduced 80% year-on-year to just $98K, with 92% reduction over 3 years; EBITDA loss improved 18% to -$395K as R&D expenses fell 21% to $874K

Recent Announcements

25 Feb 2026 Actual Results Neutral

GLH December 2025 Half Year Results Summary

Global Health Limited reported a challenging H1 FY26 with total customer revenue declining 1% to $3.6M, though Monthly Recurring Revenue (MRR) grew 2.3% to $3.3M, now comprising 92% of customer revenue. EBITDA loss improved 18% year-on-year to -$395K as R&D expenses fell 21%, and operating cash outflows were dramatically reduced 80% to just $98K. The company expects to complete its SaaS platform transition by December 2026 and forecasts additional ARR of $400K from new partnerships and product launches. Key points: Monthly Recurring Revenue increased 2.3% to $3.3M, now representing 92% of customer revenue vs 89% previously; Operating cash outflows dramatically reduced 80% year-on-year to just $98K, with 92% reduction over 3 years; EBITDA loss improved 18% to -$395K as R&D expenses fell 21% to $874K

25 Feb 2026 Actual Results Neutral

Dec 2025 Appendix 4D and Half Year Accounts

Global Health Limited reported a narrowed net loss of $629K for H1 FY26, an 8% improvement from the prior period's $687K loss. Revenue declined 1.2% to $3.6M as the company transitions from professional services to a higher-quality SaaS model, with monthly recurring revenue growing 2.3% to $3.3M. The company is pursuing profitability with reduced R&D spending and expects to operate within internally generated cashflow going forward. Key points: Net loss improved 8.4% to $629K from $687K in prior period; Monthly Recurring Revenue (MRR) grew 2.3% to $3.3M, representing 92% of customer revenue; EBITDA loss improved 18% year-on-year to $395K, showing 63% improvement over 3 years

Get real-time alerts for GLH

Receive AI-powered earnings summaries and instant notifications when Global Health Limited releases results.

Register Free